Purpose. SARS-CoV-2 vaccines efficacy and safety has been tested in phase 3 studies which did not include cancer patients. There is a lack of information regarding vaccination seroconversion and safety in this population. The objective of this study is to evaluate the seroconversion rate, safety profile and reactogenicity of the mRNA-1273 vaccine. Patients and methods. This ambispective study targeted oncologic patients having solid malignancies, who were under active treatment and received the mRNA-1273 vaccine. The first part of the study collected retrospectively demographic data from the selected patients through revision of medical records. The patients were enrolled subsequently and blood samples were collected after the second vaccine dose. Antibody titers were measured using the SARS-CoV-2 IgG II Quant assay. There was no possibility of collecting the samples within a prespecified window due to the strict COVID-19 restrictions which prevented the patients from attending to clinic. Patients were followed between April 19th and August 26th, 2021 and adverse events were registered. Results. 198 patients were selected. The group comprised 78 men (39,4%) and 120 women (60,61%). Mean age was 61 years (SD 10.67 years). We studied serological conversion in 122 patients with negative SARS-CoV-2 serologic status without prior COVID-19 infection. The median of blood collection was 61 days after second dose and the interquartile range was 18 days. Seroconversion was accomplished in 118 patients, the rate of serological conversion was 96,7%. Local reactions were the most common adverse reactions in our study population after the second dose. Systemic adverse reactions in our study population were less frequent than in the general population both after first and second vaccine dose administration. Systemic adverse reactions were more frequent after the second vaccine dose as previously reported in the general population. Conclusions. This study showed satisfactory serologic results in cancer patients after the two mRNA-1273 vaccine doses. Side effects after both doses were analyzed and some differences with the general population regarding the frequency of side effects were found.
CLO22-047: Outcomes of SARS-COV-2 mRNA-1273 Vaccine in Cancer Patients: Seroconversion and Adverse Events
© 2019-2023 National Comprehensive Cancer Network